Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC
Jingguo Sun, Yingjie Lu, Lu Chang, Ruiqun Gao, Ming Guan, Haoyu Ruan, Xuan Deng · 2026
Read Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC by Jingguo Sun, Yingjie Lu, Lu Chang, Ruiqun Gao, Ming Guan, Haoyu Ruan, Xuan Deng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13668292.txt.
Description
Jingguo Sun and co-authors review in 2026 the molecular markers that guide care for liver cancers. The review covers the main liver cancer, a bile duct cancer, and a mixed form of the two. Each type carries a different marker map. For the bile duct type, several gene changes already direct drug choice, while the main type still leans on clinical factors.
The authors sort markers by the decision each one supports, from early cure chances to tracking during treatment. They split markers into those ready for use, those for trial entry, and those still at the research stage. Value depends on timing and on whether a test can be run in practice. The review gives clinicians a decision-first map.
Catalog record
| CREATOR | Jingguo Sun, Yingjie Lu, Lu Chang, Ruiqun Gao, Ming Guan, Haoyu Ruan, Xuan Deng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |